Eradication of Helicobacter pylori. Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters
Conditions
Interventions
Intervention 1: Control group: Panto Prazol 40 mg twice daily , amoxicillin 1g , clarithromycin 500 mg twice daily for 10 days. Intervention 2: Groups intervention: pantoprazole 40 mg twice daily, amo
Treatment - Drugs
Control group: Panto Prazol 40 mg twice daily , amoxicillin 1g , clarithromycin 500 mg twice daily for 10 days
Groups intervention: pantoprazole 40 mg twice daily, amoxicillin 1 g, levofloxacin 500 mg once daily for 10 days
Sponsors
Mazandaran University of medical sciences,Deputy of Research and Technology
Eligibility
Sex/Gender
All
Age
76 Years to No maximum
Inclusion criteria
Inclusion criteria: inclusion criteria: All patients underwent endoscopy with duodenal ulcer or gastric or duodenal or stomach inflammation and Erosion referred to the clinic / office professor interviewed Sari hospital reported that Helicobacter pylori positive and study are older than 18 years Exclusion criteria: Pregnancy and breastfeeding; H. pylori eradication has already been received; During the last two weeks patients with PPI or H2 RA (histamine 2 receptor antagonist), or within the last 4 weeks have received antibiotics or bismuth; Concomitant use of anticoagulants; corticosteroids or ketoconazole; Patients with a history of stomach surgery; Patients with advanced disease confirmed and severe cardiac; pulmonary;Endocrine; chronic renal failure; chronic liver disease and cancer; alcohol consumption; With a history of peptic ulcer bleeding ulcer complications
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication of Helicobacter pylor. Timepoint: 10 days after treatment,4 Weeks after treatment ppI,Four weeks after discontinuation of medication for respiratory test. Method of measurement: Through the breath test 14 C- UBT. | — |
Secondary
| Measure | Time frame |
|---|---|
| Headache?Dizziness?Confusion. Timepoint: During the course of treatment. Method of measurement: Calling and patient interview.;Bitter mouth. Timepoint: During the course of treatment. Method of measurement: Calling and patient interview.;Diarrhea-vomiting. Timepoint: During the course of treatment. Method of measurement: Calling and patient interview.;Skin complications. Timepoint: During the course of treatment. Method of measurement: Calling and patient interview.;Nausea , abdominal pain. Timepoint: During the course of treatment. Method of measurement: Calling and patient interview.;Side effects reported by patients include hypersensitivity reactions. Timepoint: During the course of treatment. Method of measurement: Calling and patient interview.;Constipation Decreased appetite. Timepoint: During the course of treatment. Method of measurement: Calling and patient interview.;Changes in taste. Timepoint: During the course of treatment. Method of measurement: Calling and patient interview. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMr. Dr Fakheri
Mazandaran University of Medical Sciences,Deputy of Research and Technology
Outcome results
None listed